SANGAMO THERAPEUTICS INC (SGMO)
US8006771062 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -257.83M | -192.30M | -178.30M | -121.10M | -95.40M | |||
| Depreciation Amortization | 15.06M | 12.10M | 9.40M | 5.70M | 9.60M | |||
| Income Taxes - Deferred | -6.33M | N/A | N/A | N/A | N/A | |||
| Change In Working Capital | -164.03M | -82.30M | -101.90M | 252.60M | -73.00M | |||
| Other non cash items | 188.29M | 38.90M | 37.50M | 32.70M | 14.40M | |||
| OPERATING CASH FLOW | -224.84M | -223.60M | -233.30M | 169.90M | -144.40M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -21.16M | -20.20M | -23.30M | -14.70M | -20.70M | |||
| Other Investing Activity | 174.69M | 79.50M | 271.50M | -256.90M | -39.10M | |||
| INVESTING CASH FLOW | 153.53M | 59.30M | 248.20M | -271.60M | -59.80M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Stock Issued/Repurchased | 16.04M | 86.80M | 36.10M | 153.90M | 142.50M | |||
| Other Financing Activity | -1.45M | -2.10M | -3.30M | -800.00K | -400.00K | |||
| FINANCING CASH FLOW | 14.59M | 84.70M | 32.90M | 153.10M | 142.00M | |||
| Exchange Rate Effect | 1.48M | 1.30M | -300.00K | -400.00K | 200.00K | |||
| CHANGE IN CASH | -55.24M | -78.30M | 47.50M | 51.00M | -62.00M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -224.84M | -223.60M | -233.30M | 169.90M | -144.40M | |||
| Capital Expenditure | -21.16M | -20.20M | -23.30M | -14.70M | -20.70M | |||
| FREE CASH FLOW | -246.00M | -243.80M | -256.60M | 155.20M | -165.10M | |||
All data in USD